Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A universal tagging system that links data sets with the author(s) that generated them is essential to promote data sharing within the proteomics and other research communities.
Translation of human pluripotent stem cells into cell therapies will require the development of standardized tests for product consistency, stability, tumorigenicity, toxicity and immunogenicity.
Examining the relationships between invention disclosure type in industry and academia and geographical disclosure trends, using plant-made pharmaceuticals as a single-sector model for the biopharmaceutical industry.
A multilaboratory study demonstrates the potential for establishing quantitative targeted proteomic assays for moderately to highly abundant plasma proteins.
Now that ~1,000 microbial genomes have been sequenced, Nikos Kyrpides reflects on the past decade of microbial genomics and extrapolates forward to propose solutions to meeting challenges in the field.
Although multiple reaction monitoring (MRM) mass spectrometry holds considerable promise for quantifying candidate protein biomarkers in blood, transferability of MRM assays between laboratories has never been shown. Addona et al. assess the reproducibility, dynamic range and limits of detection and quantification of MRM across multiple sites.
Drug resistance remains a major hurdle to effective cancer chemotherapy. MacDiarmid et al. show that bacterially derived minicells packaged with siRNAs reverse tumor drug resistance and that subsequent treatment with minicells loaded with cytotoxic drugs causes tumor stabilization or regression.
Lipson et al. profile the yeast transcriptome using single-molecule sequencing. This approach avoids the inherent biases of the digestion, ligation and amplification steps in alternative methods based on microarrays or other sequencing technologies.
Although combinations of drugs are often more potent than single agents, they are also believed to induce worse side effects. By screening >94,000 drug pairs in vitro, Lehár et al. show that synergistic combinations tend to be more selective than single drugs and are therefore unlikely to cause synergistic side effects.
Until now, determining the sequences recognized by an RNA-binding protein has been time and labor intensive. Ray et al. use a custom pool of >210,000 oligos that encode linear and stem-loop RNAs to rapidly determine the sequences bound by nine RNA-binding proteins.